TNF receptor II fusion protein with tandemly repeated Fc domains

NAGASHIMA Hiroaki; NAGASHIMA Hiroaki; KANEKO Kaname; YAMANOI Ayaka; MOTOI Sotaro; KONAKAHARA Shu; KOHROKI Junya; KOHROKI Junya; MASUHO Yasuhiko

Art

J-GLOBAL ID：201102298022090177 Reference number：11A0728768

TNF receptor II fusion protein with tandemly repeated Fc domains

タンデム反復Fcドメインを含むTNF受容体II融合蛋白質

Publisher site {{ this.onShowPLink() }} Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=11A0728768&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A0728768&from=J-GLOBAL&jstjournalNo=W1920A") }}

Author (9)： , , , , , , , ,
Material：
Volume： 149 Issue： 3 Page： 337-346 Publication year： Mar. 2011
JST Material Number： W1920A ISSN： 0021-924X CODEN： JOBIAO Document type： Article
Article type：原著論文 Country of issue： United Kingdom (GBR) Language： ENGLISH (EN)

,...
,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A0728768&from=J-GLOBAL&jstjournalNo=W1920A") }}

Antigens,antibodies,complements in general

Reference (36)：

WANG, Y. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004, 7, 335-345
NISHIMOTO, N. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 2008, 181, 151-160
BOWLES, J. A. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006, 108, 2648-2654
DI GAETANO, N. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 2003, 171, 1581-1587
BYRD, J. C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia : evidence of caspase activation and apoptosis induction. Blood. 2002, 99, 1038-1043

ｍore...

, , ,

Return to Previous Page